Home/Stocks/CERO

CERO

USD

CERo Therapeutics Holdings Inc. Common Stock

$0.095-0.240 (-71.620%)

Real-time Price

Healthcare

Biotechnology

United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics

Company Fundamentals

Trading Stats

Market Metrics

Open

$0.335

High

$0.095

Low

$0.095

Volume

8.44M

Company Fundamentals

Market Cap

177.4K

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

2.29M

Exchange

NCM

Currency

USD

52-Week Range

Low $0.062Current $0.095High $896

Related News

Nov 3, 2025 · 07:07 PM

Analyst Upgrades

Maxim Group Downgrades CERo Therapeutics Hldgs to Hold

Maxim Group analyst Jason McCarthy downgrades CERo Therapeutics Hldgs from Buy to Hold.

Oct 30, 2025 · 11:48 AM

Analyst Upgrades

D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target

D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs with a Buy and maintains $30 price target.

Oct 29, 2025 · 11:22 PM

GlobeNewswire

CERo Therapeutics Announces Receipt of Nasdaq Panel Determination

Trading of the Company's shares of common stock on Nasdaq will be suspended at the open of trading on October 31 CERo plans to appeal the Panel determination, seek trading of its shares on the OTC Markets and continue

Oct 22, 2025 · 12:12 PM

Analyst Upgrades

D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target

D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs with a Buy and maintains $30 price target.

Oct 21, 2025 · 12:15 PM

GlobeNewswire

CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML

Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.

GlobeNewswire

Oct 15, 2025 · 12:30 PM

CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company, announces that Chris Ehrlich,